Is Kroger a Buy After Its Latest Earnings Report?

Kroger reported quarterly sales of $34.62 billion, up 2% year over year and broadly in line with the $34.65 billion consensus, while adjusted EPS of $1.09 modestly beat the $1.06 estimate. Adjusted net income fell to $667 million from $695 million, but e-commerce sales rose 20% and EPS increased from $1.04 due to a lower share count. Management cut 2026 identical-sales growth guidance to 0.2%-0.8% from 1%-2%, citing a roughly 140bp Inflation Reduction Act-related pharmacy drag, while maintaining adjusted EPS guidance of $5.10-$5.30 and continuing dividend growth and buybacks.

Analysis

KR’s maintained EPS framework despite weaker underlying traffic/sales implies that capital allocation, mix, and cost controls are doing substantial work. That supports the near-term floor but is not a clean earnings-quality positive: with gross margin already static, further pharmacy reimbursement pressure, freight inflation, or shrink deterioration would leave limited operating leverage to absorb another top-line reset. The relevant read-through is mildly negative for pharmacy-exposed grocers and wholesalers where reimbursement headwinds are less easily offset by buybacks.

The e-commerce growth figure is directionally constructive but insufficient to underwrite a multiple expansion without disclosure of digital penetration, fulfillment economics, and incremental margin. Closing fulfillment capacity may improve near-term expense absorption, yet it risks ceding convenience-led share to WMT, COST, and ACI/Albertsons in markets where delivery speed and assortment determine customer retention. KR remains a defensive cash-return story rather than a growth rerating candidate over the next 6-18 months.

For the next 1-3 months, the key catalyst is whether subsequent identical-sales trends stabilize without incremental promotional investment. Consensus may reward the preserved EPS range, but the market is likely underpricing the risk that the same levers supporting per-share earnings—repurchases and cost actions—cannot recur indefinitely if pharmacy and transport pressures persist. A guidance cut, gross-margin decline, or evidence that digital sales are dilutive would quickly reframe KR as an ex-growth staple with less room for valuation support.

Key Decisions for Investors

• Maintain KR as a low-beta defensive holding, but do not add on the modest post-results strength; require evidence of sequential identical-sales improvement and stable gross margin at the next update before upgrading to an overweight.
• Express a 1-3 month relative-value view via long WMT / short KR in equal dollar amounts: WMT has greater digital scale, advertising/profit-pool optionality, and less dependence on financial engineering. Exit if KR raises sales guidance or WMT signals material grocery margin investment.
• For existing KR longs, set a thesis alert on any reduction to the $5.10-$5.30 EPS framework or gross margin below the current run-rate; either event would indicate cost/capital-return offsets are no longer covering weak operating momentum.
• Avoid treating the dividend and remaining repurchase authorization as a standalone catalyst. Monitor net debt/EBITDA and buyback pace in the next filing; a slowdown in repurchases would expose the gap between aggregate profit growth and per-share growth.